Aa
Chinese therapeeutic "peptide" HBV vaccine
After several days of dithering, the following preliminary results have just been released:
360 HBeAg+ve patients, double-blind, random, 76 weeks, Phase 2 trial.
Rate of HBeAg seroconversion from positive to negative, with HbeAb
1. Placebo control group: 28.2%
2. 600ug group: 30%
3. 900ug group: 29.1%
360 HBeAg+ve patients, double-blind, random, 76 weeks, Phase 2 trial.
Rate of HBeAg seroconversion from positive to negative, with HbeAb
1. Placebo control group: 28.2%
2. 600ug group: 30%
3. 900ug group: 29.1%
hbeag seroconversion is such an old view parameter and if not correlated by hbsag decrease it is not a good result at all because hbsag clearance is much less, not to menthioned if hbeag negative is made by mutations to precore and bcp
since the latest results of combo int+tdf or etv hbv clearance i dont think these vaccines made any result
Just the numbers from RPS. No statements from the Board, yet.
is more like luck :)
do they mentioned if they will apply for continuing and for FDA approval ?
do they mentioned if they will apply for continuing and for FDA approval ?
This is all they have released so far. There should be a whole set of other data. Who knows when these will be released. But this set of primary results is not exactly exciting.
This is puzzle-ling.
did they publish some more detailed results ?
did they publish some more detailed results ?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
